Bempegaldesleukin
- Generic Name
- Bempegaldesleukin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1939126-74-5
- Unique Ingredient Identifier
- BNO1JG5MZC
- Background
Bempegaldesleukin is under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)).
- Associated Conditions
- -
- Associated Therapies
- -
Urothelial Carcinoma Treatment Market 2034: Clinical Trials
DelveInsight's report on Urothelial Carcinoma Market (2020-2034) highlights market trends, epidemiology, and key companies/therapies. The market size was ~USD 900 million in 2023, expected to grow significantly. Key companies include Merck, Bristol Myers Squibb, and others. Therapies like KEYTRUDA and OPDIVO are prominent. The U.S. leads in market share and incident cases. Pipeline candidates and increased awareness drive market growth.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath